ViroCell Biologics, a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy clinical trials, has appointed Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe) to drive growth in their respective regions.
Traci Kyes, as VP of Business Development (US), brings extensive experience in identifying and managing operational and commercial opportunities for life sciences CDMOs. She joins ViroCell from her role as Director of Global Business Development in the Viral Vector Service team at Thermo Fisher Scientific, a provider of viral vector CDMO services for cell and gene therapies.
Traci also has a background as Director of Business Development and VP of Commercial Operations at Arranta Bio, a biotechnology research CDMO.
Makis Sigalas, as Senior Business Development Director (Europe), has over 25 years of biopharmaceutical experience, including roles at Catalent Cell and Gene Therapy, the Cell and Gene Therapy Catapult in the UK, and as a founding partner of Omnigen Biotechnologies and Theracell Advanced Biotechnology.
These appointments strengthen ViroCell’s capabilities and support its expansion in key markets as it aims to become a preferred partner for cell and gene therapy innovators. The company focuses on providing specialized services in the development and manufacturing of therapies in the cell and gene therapy space.
These additions to the team follow other recent key appointments at ViroCell, including Brian Collins as Chief Financial Officer (CFO) and John Dawson CBE as Non-Executive Chairman, as the company continues to scale and grow its presence in the rapidly advancing field of cell and gene therapy.
ViroCell’s team will be attending the Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa in Carlsbad, California, US, showcasing its expertise in cell and gene therapy development and manufacturing.